Johnson & Johnson aims to resolve its extensive legal challenges stemming from allegations that its talc-based baby powder caused ovarian cancer. The company has proposed a $5.5 billion settlement for 76,000 lawsuits, despite denying the claims, seeking to end a decade-long legal nightmare. J&J ceased global sales of talc-based baby powder in 2023. Its strategy for brand redemption now hinges on therapeutic advances, particularly in oncology, to move beyond the significant reputational damage. This settlement, deemed fair by many, reflects J&J's effort to redefine its future.